Journal of the American Academy of Dermatology
Volume 58, Issue 4 , Pages 625-631 , April 2008

Oral curcumin in the treatment of moderate to severe psoriasis vulgaris: A prospective clinical trial

  • Shanu Kohli Kurd, MHS

      Affiliations

    • Department of Dermatology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania
    • Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania
    • ,
  • Nana Smith, MD

      Affiliations

    • Department of Dermatology, University of Rochester, Rochester, New York
    • ,
  • Abby VanVoorhees, MD

      Affiliations

    • Department of Dermatology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania
    • ,
  • Andrea B. Troxel, ScD

      Affiliations

    • Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania
    • Department of Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania
    • ,
  • Vladimir Badmaev, MD, PhD

      Affiliations

    • Sabinsa Corporation, Piscataway, New Jersey
    • ,
  • John T. Seykora, MD, PhD

      Affiliations

    • Department of Dermatology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania
    • ,
  • Joel M. Gelfand, MD, MSCE

      Affiliations

    • Department of Dermatology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania
    • Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania
    • Corresponding Author InformationCorrespondence to: Joel M. Gelfand, MD, MSCE, University of Pennsylvania School of Medicine, 2 Maloney Bldg, 3600 Spruce St, Philadelphia, PA 19104.

,Accepted 20 December 2007.

References 

  1. Gelfand JM, Weinstein R, Porter SB, Neimann AL, Berlin JA, Margolis DJ. Prevalence and treatment of psoriasis in the United Kingdom: a population-based study. Arch Dermatol. 2005;141:1537–1541
  2. Gelfand JM, Feldman SR, Stern RS, Thomas J, Rolstad T, Margolis DJ. Determinants of quality of life in patients with psoriasis: a study from the US population. J Am Acad Dermatol. 2004;51:704–708
  3. Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol. 2006;55:829–835
  4. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006;296:1735–1741
  5. Gelfand JM, Troxel AB, Lewis JD, Kurd SK, Shin DB, Wang X, et al. The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol. 2007;143:1493–1498
  6. Kurd S, Richardson S, Gelfand J. An update on the epidemiology and systemic treatment of psoriasis. Exp Rev Clin Immunol. 2007;3:171–185
  7. Greaves MW, Weinstein GD. Treatment of psoriasis. N Engl J Med. 1995;332:581–588
  8. Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc. 2004;9:136–139
  9. Gelfand JM. Long-term treatment for severe psoriasis: we're halfway there, with a long way to go. Arch Dermatol. 2007;143:1191–1193
  10. Fleischer AB, Feldman SR, Rapp SR, Reboussin DM, Exum ML, Clark AR. Alternative therapies commonly used within a population of patients with psoriasis. Cutis. 1996;58:216–220
  11. Peoples Pharmacy. Turmeric eases suffering from psoriasis. Available from: URL:http://www.healthcentral.com/peoplespharmacy/408/60710.html. Accessed September 3, 2007.
  12. Jelsoft Enterprises Ltd. Turmeric or curcumin for psoriasis? Available from: URL:http://www.psoriasis.org/forum/archive/index.php/t-15803.html. Accessed September 3, 2007.
  13. Peoples Pharmacy. Turmeric eases psoriasis. Available from: URL:http://www.buffalonews.com/opinioncolumns/columns/otherlife/story/191877.html. Accessed September 3, 2007.
  14. Singh S, Aggarwal BB. Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane). [published correction appears in J Biol Chem 1995;270:24995-5000] J Biol Chem. 1995;270:30235
  15. Brennan P, O'Neill LA. Inhibition of nuclear factor kappaB by direct modification in whole cells–mechanism of action of nordihydroguaiaretic acid, curcumin and thiol modifiers. Biochem Pharmacol. 1998;55:965–973
  16. Han SS, Keum YS, Seo HJ, Surh YJ. Curcumin suppresses activation of NF-kappaB and AP-1 induced by phorbol ester in cultured human promyelocytic leukemia cells. J Biochem Mol Biol. 2002;35:337–342
  17. Chun KS, Keum YS, Han SS, Song YS, Kim SH, Surh YJ. Curcumin inhibits phorbol ester-induced expression of cyclooxygenase-2 in mouse skin through suppression of extracellular signal-regulated kinase activity and NF-kappaB activation. Carcinogenesis. 2003;24:1515–1524
  18. Shishodia S, Potdar P, Gairola CG, Aggarwal BB. Curcumin (diferuloylmethane) down-regulates cigarette smoke-induced NF-kappaB activation through inhibition of IkappaBalpha kinase in human lung epithelial cells: correlation with suppression of COX-2, MMP-9 and cyclin D1. Carcinogenesis. 2003;24:1269–1279
  19. Chan MM. Inhibition of tumor necrosis factor by curcumin, a phytochemical. Biochem Pharmacol. 1995;49:1551–1556
  20. Jang MK, Sohn DH, Ryu JH. A curcuminoid and sesquiterpenes as inhibitors of macrophage TNF-alpha release from Curcuma zedoaria. Planta Med. 2001;67:550–552
  21. Matsuda H, Tewtrakul S, Morikawa T, Nakamura A, Yoshikawa M. Anti-allergic principles from Thai zedoary: structural requirements of curcuminoids for inhibition of degranulation and effect on the release of TNF-alpha and IL-4 in RBL-2H3 cells. Bioorg Med Chem. 2004;12:5891–5898
  22. Gulcubuk A, Altunatmaz K, Sonmez K, Haktanir-Yatkin D, Uzun H, Gurel A, et al. Effects of curcumin on tumor necrosis factor-alpha and interleukin-6 in the late phase of experimental acute pancreatitis. J Vet Med A Physiol Pathol Clin Med. 2006;53:49–54
  23. Lao CD, Ruffin MTT, Normolle D, Heath DD, Murray SI, Bailey JM, et al. Dose escalation of a curcuminoid formulation. BMC Complement Altern Med. 2006;6:10
  24. Chren MM, Lasek RJ, Quinn LM, Mostow EN, Zyzanski SJ. Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness. J Invest Dermatol. 1996;107:707–713
  25. Abeni D, Picardi A, Pasquini P, Melchi CF, Chren MM. Further evidence of the validity and reliability of the Skindex-29: an Italian study on 2,242 dermatological outpatients. Dermatology. 2002;204:43–49
  26. Carlin CS, Feldman SR, Krueger JG, Menter A, Krueger GG. A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant end point in the assessment of psoriasis. J Am Acad Dermatol. 2004;50:859–866
  27. Grant KL, Schneider CD. Turmeric. Am J Health Syst Pharm. 2000;57:1121–1122
  28. Ireson CR, Jones DJ, Orr S, Coughtrie MW, Boocock DJ, Williams ML, et al. Metabolism of the cancer chemopreventive agent curcumin in human and rat intestine. Cancer Epidemiol Biomarkers Prev. 2002;11:105–111
  29. Ammon HP, Wahl MA. Pharmacology of Curcuma longa. Planta Med. 1991;57:1–7
  30. Sharma RA, Euden SA, Platton SL, Cooke DN, Shafayat A, Hewitt HR, et al. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res. 2004;10:6847–6854
  31. Plus M. Turmeric (Curcuma longa Linn) and curcumin. Drugs and supplements. Available from: URL:http://www.nlm.nih.gov/medlineplus/druginfo/natural/patient-turmeric.html. Accessed September 3, 2007.
  32. Huang MT, Ma W, Lu YP, Chang RL, Fisher C, Manchand PS, et al. Effects of curcumin, demethoxycurcumin, bisdemethoxycurcumin and tetrahydrocurcumin on 12-O-tetradecanoylphorbol-13-acetate-induced tumor promotion. Carcinogenesis. 1995;16:2493–2497
  33. Heng MC, Song MK, Harker J, Heng MK. Drug-induced suppression of phosphorylase kinase activity correlates with resolution of psoriasis as assessed by clinical, histological and immunohistochemical parameters. Br J Dermatol. 2000;143:937–949

 Supported by departmental funds from the Hospital of the University of Pennsylvania Department of Dermatology, National Institutes of Health (NIH)/National Institute of Arthritis and Musculoskeletal Skin Diseases grant K23AR051125 (Dr Gelfand), NIH/National Center for Complementary and Alternative Medicine Ruth L. Kirschstein National Research Service Award T32-AT00600 (Dr Smith), matching funds University of Pennsylvania School of Medicine (Dr Smith), NIH K30 Center for Clinical Epidemiology and Biostatistics institutional funds (Dr Smith), contributions from various pharmaceutical manufacturers to the pharmacoepidemiology training program at the Center for Clinical Epidemiology and Biostatistics of the University of Pennsylvania (Ms Kurd), the Doris Duke Charitable Foundation (Ms Kurd), and the Clinical and Translational Research Center (Research Grant UL1RR024134 from the National Center For Research Resources) at the University of Pennsylvania. Study drug was provided by the Sabinsa Corp.

 Disclosure: Dr Gelfand has received grant support from Biogenidec, Amgen, Astellas, and Centocor. He has been a consultant for Genentech, Novartis, Warner-Chilcott, Amgen, Centocor, and Wyeth. Ms Kurd is supported by contributions from various pharmaceutical manufacturers to the pharmacoepidemiology training program at the Center for Clinical Epidemiology and Biostatistics of the University of Pennsylvania and the Doris Duke Charitable Foundation. Dr Badmaev is an employee of Sabinsa Corp. Dr VanVoorhees has received grant support from Amgen, Astellas, and Genentech and has been a consultant for Abbott, Amgen, Centocor, Genentech, and Warner-Chilcott. Dr Troxel has received grant support from Aetna and Centocor. Drs Smith and Seykora have no conflicts of interest to declare.

 Reprints not available from the authors.

PII: S0190-9622(08)00004-2

doi: 10.1016/j.jaad.2007.12.035

Journal of the American Academy of Dermatology
Volume 58, Issue 4 , Pages 625-631 , April 2008

Article Tools

* Image Usage & Resolution